Clinical Trial Detail

NCT ID NCT02769520
Title Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ezra Cohen
Indications

laryngeal squamous cell carcinoma

hypopharynx cancer

oral squamous cell carcinoma

head and neck squamous cell carcinoma

oropharynx cancer

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.